CC-486 is in development for relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL). AITL is a fast-growing type of T-cell Non-Hodgkin Lymphoma marked by enlarged lymph nodes and increased antibodies in the blood. Other symptoms may include a skin rash, fever, weight loss, or night sweats. AITL is more resistant to conventional chemotherapy than other forms of lymphoma and is generally associated with a poor outcome. In relapsed or refractory disease, survival durations are in the range of only a few months meaning there is unmet medical need in this patient population.
CC-486 is an oral drug that can be incorporated into the genetic material of cells (RNA and DNA) instead of their natural building-block, cytidine. It is thought to work by altering the way the cell turns genes on and off and also by interfering with the production of new RNA and DNA. This helps to correct the problems with the maturation and growth of young blood cells in the bone marrow and to kill cancerous cells in blood cancers. If licenced, CC-486 will provide an additional therapy option for AITL patients who have relapsed or become resistant to previous treatment.
Olaparib is administered orally in tablet form and can lead to cancer cell death by blocking DNA repair by an enzyme (protein) called PARP. By blocking PARP enzymes, the damaged DNA in cancer cells cannot be repaired, and the cells die. Abiraterone works by stopping the body making testosterone which subsequently stops the cancer growing. If licensed, this combination would provide a first-line treatment for men with mCRPC.